AR011231A1 - Uso de un mejorador de sensibilidad a la insulina y composicion farmaceutica que comprende dicho mejorador - Google Patents
Uso de un mejorador de sensibilidad a la insulina y composicion farmaceutica que comprende dicho mejoradorInfo
- Publication number
- AR011231A1 AR011231A1 ARP980105979A ARP980105979A AR011231A1 AR 011231 A1 AR011231 A1 AR 011231A1 AR P980105979 A ARP980105979 A AR P980105979A AR P980105979 A ARP980105979 A AR P980105979A AR 011231 A1 AR011231 A1 AR 011231A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- improver
- hyperuricemia
- insulin sensitivity
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
- Biological Depolymerization Polymers (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
El uso de un mejorador de sensibilidad a la insulina que se destina para la fabricacion de un medicamento para el tratamiento o prevencion de lahiperuricemia en un mamífero; y composicion farmacéutica que comprende dicho mejorador. El tratamiento inicial de los síntomas de la hiperuricemia,particularmente la gota, puede ser mediante la administracion de un agente analgésico, tal como colchicina, y/o antiinflamatorio analgésico tal comoindometacina. Es una práctica comun el tratar el problema de plazo más largo de la hiperuricemia mediante el control de la dieta, por ejemplo limitando elconsumo de alcohol o controlando el consumo de calorías. Sin embargo, si este tratamiento dietético no funciona lo suficientemente bien,la enfermedadpuede ser tratada mediante la administracion de fármacos, por ejemplo mediante la adminitracion profiláctica de un agente analgésico, tal como colchicina, opor medio de un estimulador de excrecion de ácido urico, tal como probenecid,sulfinpirazona, cetofenil-butazona, bucoloma o benzbromarona, o un inhibidorde síntesis de ácido urico tal como alopurinol. En particular, los mejoradores de sensibilidad a la insulina empleados se seleccionan preferiblemente delgrupo que consistede compuestos de tiazolidinodiona, compuestos de iminotiazolidinona, compuestos de diiminotiazolidina, compuestos detioxotiazolidinona, compuestos de iminotriazol, compuestos de oxazolidinodiona, compuestos de isoxazolidinodiona y compuestos oxadiazolidinodiona,preferiblemente los compuestos de tiazolidinodiona. Se incluyen también las sales farmacéuticamente aceptables de estos compuestos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP32318297 | 1997-11-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR011231A1 true AR011231A1 (es) | 2000-08-02 |
Family
ID=18151987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980105979A AR011231A1 (es) | 1997-11-25 | 1998-11-25 | Uso de un mejorador de sensibilidad a la insulina y composicion farmaceutica que comprende dicho mejorador |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6353009B1 (es) |
| EP (1) | EP0919232B1 (es) |
| KR (1) | KR19990045531A (es) |
| AR (1) | AR011231A1 (es) |
| AT (1) | ATE278400T1 (es) |
| AU (1) | AU744653B2 (es) |
| BR (1) | BR9805012A (es) |
| CA (1) | CA2254394C (es) |
| CZ (1) | CZ378898A3 (es) |
| DE (2) | DE69826811D1 (es) |
| ES (1) | ES2230657T3 (es) |
| HK (1) | HK1020259A1 (es) |
| HU (2) | HUP9902721A2 (es) |
| ID (1) | ID21332A (es) |
| IL (1) | IL127219A (es) |
| NO (1) | NO985484L (es) |
| NZ (1) | NZ332895A (es) |
| PL (1) | PL329893A1 (es) |
| RU (1) | RU2190425C2 (es) |
| SA (1) | SA99191266A (es) |
| TR (1) | TR199802441A2 (es) |
| TW (1) | TW592697B (es) |
| ZA (1) | ZA9810788B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6489344B1 (en) | 1998-06-19 | 2002-12-03 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| DE60043152D1 (de) * | 1999-05-27 | 2009-11-26 | Cmic Co Ltd | Heilmittel für nierenkrankheiten und verfahren zum screenen selbiger |
| US6680387B2 (en) | 2000-04-24 | 2004-01-20 | Aryx Therapeutics | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis |
| US6768008B2 (en) | 2000-04-24 | 2004-07-27 | Aryx Therapeutics | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis |
| US6958355B2 (en) | 2000-04-24 | 2005-10-25 | Aryx Therapeutics, Inc. | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis |
| AU2001294673A1 (en) | 2000-09-21 | 2002-04-02 | Aryx Therapeutics | Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, andatherosclerosis |
| ATE529110T1 (de) * | 2002-03-05 | 2011-11-15 | Transtech Pharma Inc | Mono- und bicyclische azolderivate die die interaktion von liganden mit rage hemmen |
| BRPI0410436A (pt) * | 2003-05-20 | 2006-05-30 | Transtech Pharma Inc | antagonistas de rage como agentes para amiloidose reversa e doenças associadas com a mesma |
| US20050025823A1 (en) * | 2003-07-29 | 2005-02-03 | Fong Andy A.T. | Methods of use of herbal compositions |
| JP2005092923A (ja) * | 2003-09-12 | 2005-04-07 | Renesas Technology Corp | 半導体記憶装置 |
| WO2006012438A2 (en) | 2004-07-21 | 2006-02-02 | University Of Florida Research Foundation, Inc. | Compositions and methods for treatment and prevention of insulin resistance |
| EP1919472B1 (en) * | 2005-07-21 | 2021-09-01 | University of Florida Research Foundation, Inc. | Compositions and methods for treatment and prevention of hyperuricemia related health consequences |
| MY148434A (en) * | 2007-04-05 | 2013-04-30 | Daiichi Sankyo Co Ltd | Fused bicyclic heteroaryl derivatives |
| EP2404918B1 (en) | 2009-03-05 | 2016-11-30 | Daiichi Sankyo Company, Limited | Pyridine derivative as ppary inhibitor |
| US8580833B2 (en) | 2009-09-30 | 2013-11-12 | Transtech Pharma, Inc. | Substituted imidazole derivatives and methods of use thereof |
| US8822464B2 (en) | 2011-11-28 | 2014-09-02 | Boehringer Ingelheim International Gmbh | N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors |
| US8741892B2 (en) | 2011-12-05 | 2014-06-03 | Boehringer Ingelheim International Gmbh | Compounds |
| US8846948B2 (en) | 2011-12-13 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Compounds |
| US8796467B2 (en) | 2011-12-13 | 2014-08-05 | Boehringer Ingelheim International Gmbh | Compounds |
| US8883789B2 (en) | 2011-12-14 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors |
| US8937176B2 (en) | 2011-12-14 | 2015-01-20 | Boehringer Ingelheim International Gmbh | Compounds |
| US8716277B2 (en) * | 2011-12-14 | 2014-05-06 | Boehringer Ingelheim International Gmbh | Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity |
| US8889677B2 (en) | 2012-01-17 | 2014-11-18 | Boehringer Ingellheim International GmbH | Substituted triazoles useful as mGlu5 receptor modulators |
| KR20140134266A (ko) * | 2012-01-27 | 2014-11-21 | 데이진 화-마 가부시키가이샤 | 당뇨병의 치료약 |
| EP2999800B1 (en) | 2013-05-22 | 2019-09-25 | Telomere Diagnostics Inc. | Measures of short telomere abundance |
| US20190152967A1 (en) * | 2016-04-04 | 2019-05-23 | The Schepens Eye Research Institute, Inc. | Peroxisome proliferator-activated receptor gamma selective agonists for inhibition of retinal pigment epithelium degeneration or geographic atrophy |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5522636A (en) | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
| JPS58118577A (ja) | 1982-01-07 | 1983-07-14 | Takeda Chem Ind Ltd | チアゾリジン誘導体 |
| JPS6051189A (ja) * | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | チアゾリジン誘導体およびその製造法 |
| CN1003445B (zh) | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | 噻唑烷二酮衍生物，其制备方法和用途 |
| AR240698A1 (es) * | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
| US4703052A (en) * | 1985-05-21 | 1987-10-27 | Pfizer Inc. | Hypoglycemic thiazolidinediones |
| ZA873745B (en) | 1986-06-04 | 1988-10-26 | Daiichi Seiyaku Co | Benzopyran derivatives |
| US4873255A (en) | 1987-02-04 | 1989-10-10 | Sankyo Company Limited | Thiazolidinone derivatives, their preparation and their use |
| FI91869C (fi) | 1987-03-18 | 1994-08-25 | Tanabe Seiyaku Co | Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi |
| EP0295828A1 (en) | 1987-06-13 | 1988-12-21 | Beecham Group Plc | Novel compounds |
| US5260445A (en) | 1987-09-04 | 1993-11-09 | Beecham Group P.L.C. | 2,4-thiazolidinediones |
| US5232925A (en) | 1987-09-04 | 1993-08-03 | Beecham Group P.L.C. | Compounds |
| ATE186724T1 (de) | 1987-09-04 | 1999-12-15 | Beecham Group Plc | Substituierte thiazolidindionderivate |
| US5194443A (en) | 1987-09-04 | 1993-03-16 | Beecham Group P.L.C. | Compounds |
| WO1989008651A1 (en) * | 1988-03-08 | 1989-09-21 | Pfizer Inc. | Hypoglycemic thiazolidinedione derivatives |
| WO1989008650A1 (en) | 1988-03-08 | 1989-09-21 | Pfizer Inc. | Thiazolidinedione hypoglycemic agents |
| US5120754A (en) | 1988-03-08 | 1992-06-09 | Pfizer Inc. | Thiazolidinedione hypoglycemic agents |
| US5223522A (en) | 1988-03-08 | 1993-06-29 | Pfizer Inc. | Thiazolidinedione hypoglycemic agents |
| US5155114A (en) * | 1989-01-23 | 1992-10-13 | Fujisawa Pharmaceutical Company, Ltd. | Method of treatment using pyrazolopyridine compound |
| US4897405A (en) | 1989-04-21 | 1990-01-30 | American Home Products Corporation | Novel naphthalenylalkyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents |
| GB8919434D0 (en) | 1989-08-25 | 1989-10-11 | Beecham Group Plc | Novel compounds |
| WO1991007107A1 (en) | 1989-11-13 | 1991-05-30 | Pfizer Inc. | Oxazolidinedione hypoglycemic agents |
| JPH0469383A (ja) | 1990-07-06 | 1992-03-04 | Yamanouchi Pharmaceut Co Ltd | 置換チアゾリジン誘導体 |
| GB9017218D0 (en) | 1990-08-06 | 1990-09-19 | Beecham Group Plc | Novel compounds |
| EP0648242B1 (en) * | 1992-07-02 | 1997-05-02 | Novo Nordisk A/S | POLYMERIZATION OF LIGNIN AT ALKALINE pH |
| GB9223059D0 (en) | 1992-11-04 | 1992-12-16 | Bamford Excavators Ltd | Intercooler apparatus |
| JP2845743B2 (ja) | 1992-12-28 | 1999-01-13 | 三菱化学株式会社 | 新規なナフタレン誘導体 |
| JPH06211657A (ja) | 1993-01-21 | 1994-08-02 | Mochida Pharmaceut Co Ltd | 尿酸排泄剤 |
| EP1714652A3 (en) | 1993-09-15 | 2007-01-17 | Sankyo Company, Limited | Use of thiazolidinediones to prevent or delay onset of niddm |
| CA2157032C (en) | 1993-12-27 | 1999-09-28 | Hisashi Shinkai | Isoxazolidinedione derivative and use thereof |
| RU2151145C1 (ru) | 1994-04-11 | 2000-06-20 | Санкио Компани Лимитед | Промежуточное соединение для получения гетероциклических соединений, обладающих антидиабетической активностью |
| US5703096A (en) | 1994-10-07 | 1997-12-30 | Sankyo Company, Limited | Oxime derivatives, their preparation and their therapeutic use |
| IL118474A (en) | 1995-06-01 | 2001-08-08 | Sankyo Co | Benzimideol derivatives and pharmaceutical preparations containing them |
| US5929055A (en) * | 1997-06-23 | 1999-07-27 | The Research Foundation Of State University Of New York | Therapeutic method for management of diabetes mellitus |
-
1997
- 1997-03-25 HU HU9902721A patent/HUP9902721A2/hu unknown
-
1998
- 1998-11-18 AT AT98309426T patent/ATE278400T1/de not_active IP Right Cessation
- 1998-11-18 ES ES98309426T patent/ES2230657T3/es not_active Expired - Lifetime
- 1998-11-18 DE DE69826811A patent/DE69826811D1/de not_active Expired - Lifetime
- 1998-11-18 US US09/195,031 patent/US6353009B1/en not_active Expired - Fee Related
- 1998-11-18 EP EP98309426A patent/EP0919232B1/en not_active Expired - Lifetime
- 1998-11-18 DE DE69826811T patent/DE69826811T4/de not_active Expired - Lifetime
- 1998-11-19 NZ NZ332895A patent/NZ332895A/en unknown
- 1998-11-20 CZ CZ983788A patent/CZ378898A3/cs unknown
- 1998-11-23 IL IL12721998A patent/IL127219A/en not_active IP Right Cessation
- 1998-11-24 NO NO985484A patent/NO985484L/no not_active Application Discontinuation
- 1998-11-24 ID IDP981528A patent/ID21332A/id unknown
- 1998-11-24 CA CA002254394A patent/CA2254394C/en not_active Expired - Fee Related
- 1998-11-24 TW TW087119452A patent/TW592697B/zh not_active IP Right Cessation
- 1998-11-24 RU RU98121310/14A patent/RU2190425C2/ru not_active IP Right Cessation
- 1998-11-24 BR BR9805012A patent/BR9805012A/pt not_active Application Discontinuation
- 1998-11-24 KR KR1019980050484A patent/KR19990045531A/ko not_active Application Discontinuation
- 1998-11-25 PL PL98329893A patent/PL329893A1/xx unknown
- 1998-11-25 TR TR1998/02441A patent/TR199802441A2/xx unknown
- 1998-11-25 AR ARP980105979A patent/AR011231A1/es unknown
- 1998-11-25 ZA ZA9810788A patent/ZA9810788B/xx unknown
- 1998-11-25 HU HU9802721A patent/HUP9802721A1/hu unknown
- 1998-11-25 AU AU94102/98A patent/AU744653B2/en not_active Ceased
-
1999
- 1999-04-06 SA SA99191266A patent/SA99191266A/ar unknown
- 1999-11-22 HK HK99105394A patent/HK1020259A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IL127219A0 (en) | 1999-09-22 |
| TW592697B (en) | 2004-06-21 |
| AU744653B2 (en) | 2002-02-28 |
| HUP9802721A1 (hu) | 2000-03-28 |
| EP0919232A1 (en) | 1999-06-02 |
| NO985484D0 (no) | 1998-11-24 |
| CA2254394A1 (en) | 1999-05-25 |
| KR19990045531A (ko) | 1999-06-25 |
| US6353009B1 (en) | 2002-03-05 |
| ZA9810788B (en) | 1999-05-25 |
| DE69826811D1 (de) | 2004-11-11 |
| CZ378898A3 (cs) | 1999-07-14 |
| RU2190425C2 (ru) | 2002-10-10 |
| SA99191266A (ar) | 2005-12-03 |
| BR9805012A (pt) | 2000-03-21 |
| NO985484L (no) | 1999-05-26 |
| NZ332895A (en) | 2001-04-27 |
| AU9410298A (en) | 1999-06-17 |
| DE69826811T2 (de) | 2005-06-16 |
| HUP9902721A2 (hu) | 1999-12-28 |
| HK1020259A1 (en) | 2000-04-07 |
| ATE278400T1 (de) | 2004-10-15 |
| TR199802441A3 (tr) | 1999-10-21 |
| CA2254394C (en) | 2009-11-17 |
| EP0919232B1 (en) | 2004-10-06 |
| TR199802441A2 (xx) | 1999-10-21 |
| ID21332A (id) | 1999-05-27 |
| PL329893A1 (en) | 1999-06-07 |
| DE69826811T4 (de) | 2006-09-21 |
| ES2230657T3 (es) | 2005-05-01 |
| HU9802721D0 (en) | 1999-01-28 |
| IL127219A (en) | 2001-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR011231A1 (es) | Uso de un mejorador de sensibilidad a la insulina y composicion farmaceutica que comprende dicho mejorador | |
| NO981628L (no) | (Metylsulfonyl)fenyl-2-(5H)-furanoner som cox-2 inhibitorer | |
| IT1245889B (it) | Formulazioni farmaceutiche per uso orale gastroresistenti contenenti sali di acidi biliari. | |
| ATE397602T1 (de) | 9-(piperazinylalkyl)carbazole als bax-modulatoren | |
| CU20000176A7 (es) | Composiciones de celecoxib | |
| DK0828724T3 (da) | 5-oxygenerede diaryl-2-(5H)-furanoner som COX-2-inhibitorer | |
| BRPI0317463B8 (pt) | composto, composição farmacêutica compreendendo o mesmo e uso do referido composto no preparo de um medicamento para tratar uma doença amilóide de transtiretina | |
| CY1107384T1 (el) | Ταχεως διασπειρομενες μορφες δοσομετρησεως ανευ ζελατινης | |
| NO20032734D0 (no) | Nye 1,2-difenylazetidinonderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder nevnte forbindelser og anvendelse avdisse for behandling av sykdommer fra lipidstoffskiftet | |
| BR0209468A (pt) | Composto ou sais ou solvatos deste farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada pelo hppar | |
| BR0116370A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente. | |
| HUP0200714A2 (hu) | Gyógyhatású vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0402506A2 (hu) | FBPáz inhibitorok és inzulinérzékenység-fokozók kombinációja diabétesz kezelésére | |
| BR9809968A (pt) | Aplicação de derivados tiazolidinadiona no tratamento da pcos e diabetes gestacional | |
| IT1245891B (it) | Formulazioni farmaceutiche a rilascio controllato per uso orale gastroresistenti contenenti acidi biliari e loro sali. | |
| DK1546127T3 (da) | Nye pyrimidinamidderivater og anvendelse deraf | |
| YU50401A (sh) | Farmaceutski sastav koji sadrži inhibitore protonske pumpe | |
| BR0315662A (pt) | Derivados de 1-(4-benzil-piperazin-1-il)-3-fenil-propenona | |
| CY1107753T1 (el) | 2,5-δισυποκατεστημενο 3-μερκαπτοπεντανοϊκο οξυ | |
| CL2003002293A1 (es) | Compuestos derivados de indazol; su composicion farmaceutica; su uso en el tratamiento de hipertension ocular. | |
| DK0652874T3 (da) | 2-heterocycliske-5-hydroxy-1,3-pyrimidiner der er nyttige som antiinflammatoriske midler | |
| Wang et al. | Evaluation of Anti‐inflammatory and Analgesic Effects of Synthesized Derivatives of Ibuprofen | |
| US20170029388A1 (en) | Treatment of Neurodegenerative Diseases with Asparagine Endopeptidase (AEP) Inhibitors and Compositions Related Thereto | |
| ATE244232T1 (de) | (methylsulfonyl)phenyl-2-(5h)-furanone mit sauerstoff-bindung als cox-2-hemmer | |
| BR0312943A (pt) | Combinação de um inibidor alostérico de matriz metaloproteinase-13 com um inibidor seletivo de ciclooxigenase-2 que não é celecoxib ou valdecoxib |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |